New drug combo aims to outsmart advanced prostate cancer

NCT ID NCT07002320

Recruiting now Disease control Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for men with a type of advanced prostate cancer that has spread and no longer responds to standard hormone therapy. It tests whether adding a new drug called SX-682 to the existing drug apalutamide is safe and can shrink tumors or slow the cancer. About 78 men will take part in this early-phase trial to find the right dose and see if the combination works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATE RESISTANT PROSTATE CANCER (MCRPC)

Contacts and locations

Locations

Belfast Health and Social Care Trust
RECRUITING

Belfast, BT9 7AB, United Kingdom
Cambridge University Hospitals NHS Foundation Trust
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Oncology Institute of Southern Switzerland
NOT_YET_RECRUITING

Bellinzona, CH6500, Switzerland
The Royal Marsden NHS Foundation Trust - Drug Development Unit
RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.